Many of the world’s biggest selling drugs have lost exclusivity in recent years, presenting huge opportunities for generic drugs companies but, as LSIPR finds out, it doesn’t have to be a dead end for the innovators.
At first glance, the phenomenon of losing exclusivity is a boon for the generic manufacturers which plan to market their own versions, but there are hidden pitfalls along the way.
“To some extent people are looking at the so-called ‘patent cliff’ as good news for generics and bad news for innovators but I think the situation is a little more nuanced than that,” says Warwick Smith, director general of the British Generics Manufacturing Association.
Once the world’s biggest selling drug, atorvastatin (brand name Lipitor) is prescribed to lower cholesterol, and can reduce the risk of heart attack and stroke. In its heyday, it achieved sales of more than $12 billion a year for Pfizer.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Patent cliff, Lipitor, Pfizer, Hatch-Waxman Act, generics